Gilead to buy biotech firm for $21 billion

Gilead Sciences will acquire biotech company Immunomedics for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday. The deal will give Gilead access to Immunomedics' breast cancer treatment drug Trodelvy.